On Wednesday, Oppenheimer maintained its Perform rating for Benson Hill, Inc. (NASDAQ: BHIL), a company specializing in plant-based technology. The commentary from the analyst highlighted that Benson Hill's third-quarter results are in line with expectations for 2024 as a transitional period, as the company phases out its legacy grain sales.
Benson Hill is preparing for significant growth with the anticipation of over 30 soybean varieties becoming available in 2025. This expansion is projected to increase the company's scale to more than 450,000 acres, representing a 60% growth year-over-year. This scale-up is a key step towards establishing Benson Hill's asset-light licensing model for the future.
During the third quarter, the company continued to make progress in its pilot programs, particularly noting strong feed conversion results in poultry. Benson Hill's pro forma revenue growth was attributed to an uptick in genetic licensing and distribution, alongside continued variety expansion.
Despite these advancements, the firm pointed out that capitalization remains a primary challenge for Benson Hill. The company has not provided any new updates regarding potential capital sources since the non-binding offer it received in June. Nevertheless, the analyst expressed optimism that Benson Hill is considering all available options to address its capital needs.
In other recent news, Benson Hill Inc (NASDAQ:BHIL). has seen significant developments. The company announced the resignation of J. Stephan Dolezalek from its Board of Directors, with no disagreements cited as a reason for his departure.
Concurrently, Benson Hill terminated its exclusive agreement with Archer-Daniels-Midland Company (NYSE:ADM), opting for a non-exclusive seed supply contract. This strategic move allows the company to commercialize and sell certain proprietary high-protein soybean seed varieties.
Benson Hill has also executed a reverse stock split at a 1-for-35 ratio, reducing its outstanding shares from approximately 213 million to around 6 million, while maintaining unchanged voting power and business operations.
The company is also exploring strategic alternatives, including a potential sale, following a preliminary indication of interest from Argonautic Ventures Master SPC and other co-investors. A special committee has been formed to review these alternatives, and a non-binding letter of intent has been executed with Argonautic, outlining terms of a possible acquisition.
These recent developments highlight Benson Hill's ongoing efforts to diversify its partnerships and expand its market reach within the agricultural sector.
InvestingPro Insights
While Oppenheimer maintains a Perform rating for Benson Hill, Inc. (NASDAQ: BHIL), recent data from InvestingPro paints a more nuanced picture of the company's financial health. Despite the company's ambitious growth plans and progress in pilot programs, several key metrics suggest caution.
According to InvestingPro data, Benson Hill's revenue for the last twelve months as of Q2 2024 stood at $456.09 million, with a notable revenue growth of 55.33% over the same period. This aligns with the company's reported progress in genetic licensing and distribution. However, the company's gross profit margin remains low at 4.85%, which may be a concern as it scales up operations.
InvestingPro Tips highlight that Benson Hill is "quickly burning through cash" and "may have trouble making interest payments on debt." These factors could exacerbate the capitalization challenges mentioned in the analyst's report. Additionally, the tip indicating that "analysts do not anticipate the company will be profitable this year" underscores the importance of the company's efforts to address its capital needs.
It's worth noting that InvestingPro offers 13 additional tips for Benson Hill, providing a more comprehensive analysis for investors considering the stock's potential. As the company navigates its transitional period and prepares for future growth, these insights could prove valuable in assessing its long-term prospects.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.